Loading startup

DealFlow OS
Market indexPublic companiesMorning briefingTerminal
Request accessSign in

DealFlow

Terminal access

IndexTop moversSignals

Public markets

Public companiesMorning briefing
Browse index
G

General Proximity

SeedFunding signal
www.generalproximity.bio/HealthcareSan Francisco, CA, USA
Market index

Market data is refreshed once per day from public sources. Information may be incomplete or outdated — verify independently before making decisions. This is not investment advice.

Investor read

Evidence-bound summary — expand sections for movement, risks, and signals.

Memo snapshot · May 20, 2026, 6:26 PM

Worth a meetingEvidence-bound analyst verdict
  • •Funding: Raised $16M across 1 funding round. Latest: $16M Seed (Jan 2025). Investors: Felicis, Y Combinator, age1, Modi Ventures, Wilson Sonsini.
  • •Named backers in indexed sources: Felicis to advance OmniTAC proximity medicines for undruggable targets, Felicis, Y Combinator, age1.
  • •Hiring: 1 hiring‑related row(s); role‑spam risk if mostly generic boards
  • •Product/news: 1 product/news‑styled row(s); headline risk without filings

DealFlow OS uses public web data and automated enrichment. Research may be incomplete, outdated, or incorrect. Verify important information before making investment or outreach decisions.

TL;DR

Unknown

General Proximity

Funding

Raised $16M across 1 funding round. Latest: $16M Seed (Jan 2025). Investors: Felicis, Y Combinator, age1, Modi Ventures, Wilson Sonsini. (High).

Quick read

  • •General Proximity
  • •Reported angle: Latest News & Insights | General Proximity

Key signals

Funding

Raised $16M across 1 funding round. Latest: $16M Seed (Jan 2025). Investors: Felicis, Y Combinator, age1, Modi Ventures, Wilson Sonsini. (High).

Hiring

1 hiring‑related row(s); role‑spam risk if mostly generic boards (Low).

Product / news

1 product/news‑styled row(s); headline risk without filings (High).

Evidence summary

Verified facts

  • •General Proximity
  • •Reported angle: Latest News & Insights | General Proximity

Recent movers

  • •May 20, 2026 · generalproximity.bio — General Proximity De-Stealths with $16M
  • •May 20, 2026 · generalproximity.bio — Latest News & Insights | General Proximity
  • •May 11, 2026 · Careers — Careers in Next-Gen Medicine | General Proximity
  • •May 20, 2026 · generalproximity.bio — General Proximity De-Stealths with $16M
  • •May 20, 2026 · generalproximity.bio — Latest News & Insights | General Proximity
  • •May 11, 2026 · Careers — Careers in Next-Gen Medicine | General Proximity
  • •Felicis to advance OmniTAC proximity medicines for undruggable targets
  • •Felicis
  • •Y Combinator
  • •age1
  • •Modi Ventures
  • •Wilson Sonsini

Suggested next steps

  • ▸Open a founder conversation this month; validate traction claims against the indexed evidence.
  • ▸Add to the active watchlist so new signals trigger alerts.

Funding & hiring signals

fundingConfidence: high

Funding mention on Latest News & Insights | General Proximity

Latest News & Insights | General Proximity Team Careers News Latest News subscribe Subscribe All announcements Press Blog Press FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity Investment reflects General Proximity's strong scientifi

Affected score: noObserved: Jun 29, 2026
funding_articleMay 20, 2026Confidence: high

General Proximity De-Stealths with $16M

$16M seed led by Felicis to advance OmniTAC proximity medicines for undruggable targets.

Affected score: yesObserved: May 20, 2026Round: SeedAmount: $16M
raisedseed

Open roles (indexed)

No open roles indexed yet.

Public index
85Activity 86/100Strong public activity signal
7D+8 (+10.4%)
30D+34 (+66.7%)
High Confidence

The index price and activity score are algorithmic estimates based on observed public company-level signals. They may be incomplete, stale, or inaccurate and are not investment, legal, tax, or business advice.

Source health

  • public_page:newsok
    Last checked Thu, Jul 2, 03:38 PM
  • public_page:blogok
    Last checked Thu, Jul 2, 03:38 PM
  • public_page:jobsok
    Last checked Thu, Jul 2, 03:38 PM
  • public_page:careersok
    Last checked Thu, Jul 2, 03:38 PM
  • public_page:homeok
    Last checked Thu, Jul 2, 03:38 PM
  • public_page:teamok
    Last checked Mon, Jun 29, 06:58 AM
  • public_market_enrichmentok
    Last checked Mon, May 11, 05:06 AM
  • public_page:_newsok
    Last checked Mon, May 11, 05:06 AM
  • public_page:_jobsok
    Last checked Mon, May 11, 05:06 AM
  • public_page:_careersok
    Last checked Mon, May 11, 05:06 AM
  • public_page:_blogok
    Last checked Mon, May 11, 05:06 AM
  • public_page:_ok
    Last checked Mon, May 11, 05:06 AM

Signal timeline

12 dated public signals · newest on the right

Funding
Hiring
Press
Company
Dec 10, 2024Oct 2, 2025Jul 24, 2026
Funding (2)Hiring (1)Press (2)Company (7)

Signal breakdown

Latest momentum signal per category. Expand a card to inspect raw payloads.

Public source summary

Total evidence rows
12
Latest evidence
Thu, Jul 2, 03:38 PM

Source types found

blogfundingfunding_articlehiringnewsofficial_site

Strongest / recent news-style rows

  • Latest News & Insights | General Proximity

    News · Thu, Jul 2, 03:38 PM · confidence 90%high quality

  • Funding mention on Latest News & Insights | General Proximity

    official_site_funding · Mon, Jun 29, 06:58 AM · confidence 80%high quality

  • General Proximity De-Stealths with $16M

    Wed, May 20, 06:26 PM · confidence 88%high quality

Public signal timeline

Newest first · 12 event(s)

1
Thu, Jul 2, 03:38 PM · news · 90% · publichigh qualityLatest News & Insights | General Proximity

Source: News

Stay updated on General Proximity’s breakthroughs, news, and innovations in next-gen medicines redefining biology and drug discovery.

Source ↗
2
Thu, Jul 2, 03:38 PM · blog · 70% · publichigh qualityGeneral Proximity | Armand B. Cognetta III | Substack

Source: Blog

generalproximity.bio blog. Click to read General Proximity, by Armand B. Cognetta III, a Substack publication with thousands of subscribers.

Source ↗
3
Thu, Jul 2, 03:38 PM · hiring · 70% · publichigh qualityCareers in Next-Gen Medicine | General Proximity

Source: Jobs page

Join General Proximity and help redefine the future of medicine. Explore career opportunities in proximity-based drug innovation and groundbreaking biology.

Source ↗
4
Thu, Jul 2, 03:38 PM · official_site · 90% · publichigh qualityNext-Gen Proximity Medicines | General Proximity

Source: Homepage

General Proximity pioneers next-generation medicines by controlling biological processes through proximity. Redefining the future of medicine for all humankind.

Source ↗
5
Mon, Jun 29, 06:58 AM · official_site · 75% · publichigh qualityCareers in Next-Gen Medicine | General Proximity

Source: official_site

Careers in Next-Gen Medicine | General Proximity Team Careers News Empowering proximity Join our journey to redefine the future of medicine. Open positions Heading Heading Lorem ipsum dolor Apply Newsletter Subscribe Subscribe Newsletter Thanks for subscribin…

Source ↗
6
Mon, Jun 29, 06:58 AM · official_site · 75% · publichigh qualityGeneral Proximity | Armand B. Cognetta III | Substack

Source: official_site

General Proximity | Armand B. Cognetta III | Substack General Proximity generalproximity.bio blog By Armand B. Cognetta III · Over 7,000 subscribers Subscribe By subscribing, you agree Substack's Terms of Use , and acknowledge its Information Collection Notic…

Source ↗
7
Mon, Jun 29, 06:58 AM · official_site · 75% · publichigh qualityLatest News & Insights | General Proximity

Source: official_site

Latest News & Insights | General Proximity Team Careers News Latest News subscribe Subscribe All announcements Press Blog Press FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity Investment reflects General Proximity&#x…

Source ↗
8
Mon, Jun 29, 06:58 AM · official_site · 75% · publichigh qualityCareers in Next-Gen Medicine | General Proximity

Source: official_site

Careers in Next-Gen Medicine | General Proximity Team Careers News Empowering proximity Join our journey to redefine the future of medicine. Open positions Heading Heading Lorem ipsum dolor Apply Newsletter Subscribe Subscribe Newsletter Thanks for subscribin…

Source ↗
9
Mon, Jun 29, 06:58 AM · funding · 80% · publichigh qualityFunding mention on Latest News & Insights | General Proximity

Source: official_site_funding

Latest News & Insights | General Proximity Team Careers News Latest News subscribe Subscribe All announcements Press Blog Press FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity Investment reflects General Proximity&#x…

Source ↗
10
Mon, Jun 29, 06:58 AM · official_site · 75% · publichigh qualityNext-Gen Proximity Medicines | General Proximity

Source: official_site

Next-Gen Proximity Medicines | General Proximity Team Careers News Nothing Programmable medicines for all mankind. is Undruggable Programmable medicines for all mankind. Control Proximity , Control Biology First Principles: All biological processes are driven…

Source ↗
11
Mon, Jun 29, 06:58 AM · official_site · 75% · publichigh qualityMeet Our Team | General Proximity

Source: official_site

Meet Our Team | General Proximity logo link Team Careers News Proximity pioneers We’ve assembled a world-class team of proximity scientists from Scripps, the Broad Institute, Harvard, MIT, Yale, Oxford, and UCSF, with industry experience across top pharma and…

Source ↗
12
Wed, May 20, 06:26 PM · funding_article · 88% · verified_publichigh qualityGeneral Proximity De-Stealths with $16M

$16M seed led by Felicis to advance OmniTAC proximity medicines for undruggable targets.

Source ↗

Official / company site

7 row(s)

The company's own site — the authoritative description of what they sell and to whom. Marketing-controlled, so treat claims as positioning rather than verified traction.

official_site·Thu, Jul 2, 03:38 PM·Confidence 90%high qualitypublic
Next-Gen Proximity Medicines | General Proximity

General Proximity pioneers next-generation medicines by controlling biological processes through proximity. Redefining the future of medicine for all humankind.

Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.

Open source ↗
official_site·Mon, Jun 29, 06:58 AM·Confidence 75%high qualitypublic
Careers in Next-Gen Medicine | General Proximity

Careers in Next-Gen Medicine | General Proximity Team Careers News Empowering proximity Join our journey to redefine the future of medicine. Open positions Heading Heading Lorem ipsum dolor Apply Newsletter Subscribe Subscribe Newsletter Thanks for subscribin…

Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.

Open source ↗
official_site·Mon, Jun 29, 06:58 AM·Confidence 75%high qualitypublic
General Proximity | Armand B. Cognetta III | Substack

General Proximity | Armand B. Cognetta III | Substack General Proximity generalproximity.bio blog By Armand B. Cognetta III · Over 7,000 subscribers Subscribe By subscribing, you agree Substack's Terms of Use , and acknowledge its Information Collection Notic…

Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.

Open source ↗
official_site·Mon, Jun 29, 06:58 AM·Confidence 75%high qualitypublic
Latest News & Insights | General Proximity

Latest News & Insights | General Proximity Team Careers News Latest News subscribe Subscribe All announcements Press Blog Press FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity Investment reflects General Proximity&#x…

Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.

Open source ↗
official_site·Mon, Jun 29, 06:58 AM·Confidence 75%high qualitypublic
Careers in Next-Gen Medicine | General Proximity

Careers in Next-Gen Medicine | General Proximity Team Careers News Empowering proximity Join our journey to redefine the future of medicine. Open positions Heading Heading Lorem ipsum dolor Apply Newsletter Subscribe Subscribe Newsletter Thanks for subscribin…

Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.

Open source ↗
official_site·Mon, Jun 29, 06:58 AM·Confidence 75%high qualitypublic
Next-Gen Proximity Medicines | General Proximity

Next-Gen Proximity Medicines | General Proximity Team Careers News Nothing Programmable medicines for all mankind. is Undruggable Programmable medicines for all mankind. Control Proximity , Control Biology First Principles: All biological processes are driven…

Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.

Open source ↗
official_site·Mon, Jun 29, 06:58 AM·Confidence 75%high qualitypublic
Meet Our Team | General Proximity

Meet Our Team | General Proximity logo link Team Careers News Proximity pioneers We’ve assembled a world-class team of proximity scientists from Scripps, the Broad Institute, Harvard, MIT, Yale, Oxford, and UCSF, with industry experience across top pharma and…

Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.

Open source ↗

News

1 row(s)

Third-party press coverage. Independent reporting corroborates company claims; repeated coverage across outlets is a momentum signal.

news·Thu, Jul 2, 03:38 PM·Confidence 90%high qualitypublic
Latest News & Insights | General Proximity

Stay updated on General Proximity’s breakthroughs, news, and innovations in next-gen medicines redefining biology and drug discovery.

Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.

Open source ↗

Funding / news

2 row(s)

Funding announcements and investor-database records. The strongest public signal of capitalization: round, amount, and syndicate quality when disclosed.

funding·Mon, Jun 29, 06:58 AM·Confidence 80%high qualitypublic
Funding mention on Latest News & Insights | General Proximity

Latest News & Insights | General Proximity Team Careers News Latest News subscribe Subscribe All announcements Press Blog Press FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity Investment reflects General Proximity&#x…

Why it matters: Funding signal — seed per this source; verify against the linked original before relying on it.

Open source ↗
funding_article·Wed, May 20, 06:26 PM·Confidence 88%high qualityverified_public
General Proximity De-Stealths with $16M

$16M seed led by Felicis to advance OmniTAC proximity medicines for undruggable targets.

Why it matters: Funding signal — Seed per this source; verify against the linked original before relying on it.

Open source ↗

Hiring

1 row(s)

Open roles and careers pages. Active hiring implies runway to spend and shows where the company is investing (engineering vs GTM vs ops).

hiring·Thu, Jul 2, 03:38 PM·Confidence 70%high qualitypublic
Careers in Next-Gen Medicine | General Proximity

Join General Proximity and help redefine the future of medicine. Explore career opportunities in proximity-based drug innovation and groundbreaking biology.

Why it matters: Hiring signal — open roles imply runway to spend and show where the company is investing.

Open source ↗

Blog

1 row(s)

Company blog and newsletters. Shipping cadence and technical depth of posts hint at product velocity and team quality.

blog·Thu, Jul 2, 03:38 PM·Confidence 70%high qualitypublic
General Proximity | Armand B. Cognetta III | Substack

generalproximity.bio blog. Click to read General Proximity, by Armand B. Cognetta III, a Substack publication with thousands of subscribers.

Why it matters: Company publishing — post cadence and depth hint at product velocity.

Open source ↗

Private workspace

Sign in as an active team member to view private notes, watchlist controls, transcript evidence, and interaction history.

Sign in
DealFlow OS · Public market terminal
Privacy PolicyTerms & Conditions